

1 September 2020

ASX Code: MXC

Strategic Biopharma industry appointments strengthen Board and leadership team

A
S
X

R
E
L
E
A
S
E

Key Highlights:

- Evan Hayes appointed as an independent Non-Executive Director to the Board, bringing 20+ years of commercial healthcare and biotechnology experience, including senior executive roles within Blackmores Limited
- Mr Hayes will also be engaged in a strategic advisory role with the Company, to advise on global commercialisation strategy of the Company's cannabinoid medicine products and ArtemiC™
- Sabina Suljaković appointed as Qualified Person and Head of Quality Unit at our EU GMP facility in Slovenia ensuring all strict EU production guidelines are met. Sabina previously managed the product quality division at PharmaSwiss
- Amir Polak, appointed as Chief Technology Officer and Head of Pharmaceutical Production bringing 10+ years' experience in the biopharma sector. Amir was previously head of chemical production at Nano-Dimension, and project co-ordinator for Teva Pharmaceuticals
- Appointments ensure MXC is well placed to continue its growth strategy and become a leading manufacturer of high-quality, EU GMP phytocannabinoid-derived medicine products

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), a European based biopharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce it has strengthened its Board and leadership team with biopharma industry expertise following the appointment of Evan Hayes as an Independent Non-Executive Director and Strategic Advisor, Sabina Suljaković as Qualified Person and Head of the Quality Assurance in Slovenia and Amir Polak as Chief Technology Officer and Head of Pharmaceutical Production.

These appointments are strategically important for MXC as the Company continues to build a high-quality biopharma team. All three members bring extensive knowledge of the biopharma industry and accelerate the delivery of MXC's growth strategy to become a leading biopharma company that produces and manufactures high-quality medicinal cannabis products that are available globally.

Evan Hayes appointed as Independent Non-Executive Director and Strategic Advisor

Evan Hayes is a highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes graduated with a Master of Science 1st Class Honours (Biotechnology) from the National University of Ireland, Galway and prior to this he finished first in his class from the National University of Ireland, Cork with a Bachelor of Science degree (Honours). Mr Hayes' has also won the Daniel O'Carroll Award for Scientific Research.

Mr Hayes is currently the Asia Pacific Managing Director of Factors Group, Canada's largest natural health company. Prior to this Mr Hayes was the Director of Sourcing and Product Development at Australia's largest natural health company, Blackmores, leading the Procurement, Technical, New product development, and Strategic sourcing divisions and managed a budget of \$250m.

Mr Hayes was also Executive Director, Chairman of the Scientific Advisory Board and Chief Scientific Officer of BioCeuticals, part of the Blackmores group, where he led the product development team which delivered sales from new product development of over \$120m in 5 years. During his career, Mr Hayes has worked across Europe, the USA and in Australia and has exceptionally strong knowledge of both the FDA and the TGA regulation.

Mr Hayes will receive the standard Non-Executive Director fee of \$48k per annum and the Board will be finalising terms of the engagement as Strategic Advisor to include an incentive equity package, the Company will update the market on these details once agreed.

Key Pharma industry appointments to the senior management and production team

Additionally, Sabina Suljaković joins MXC as a Qualified Person and Head of the Quality Assurance Department at the Company’s EU GMP facility in Slovenia and Amir Polak has joined as Chief Technology Officer and Head of Pharmaceutical Production.

Sabina brings vast experience in the quality leadership from her previous managerial roles at leading pharmaceutical companies which includes PharmaSwiss (a Bausch Health company). Sabina’s experience will be vital in taking the Company to its next phase of growth by ensuring the highest quality standards are achieved. This is aligned with the Company’s ambition of producing high-quality phytocannabinoid medicine to meet all strict EU regulatory requirements. Sabina holds MSc in Pharmacy from the University of Ljubljana, is a registered Pharmacist at the Ministry of Health and registered Qualified Person and Responsible Person at the Slovenian Agency for medicines and medical devices.

Amir was previously part of the senior leadership team and co-founder at Green City Ltd, head of chemical production at Nano-Dimension, project co-ordinator for Teva Pharmaceuticals and has been a consultant in the industry for over 10 years. Amir brings extensive production experience to the Company and is specialised in "Lab to Plant" development of complex projects. Amir holds MSc in Chemistry from the Hebrew University-Jerusalem. Amir has been consulting with MGC Pharma and is now full time.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We are delighted to welcome Evan, Sabina and Amir to MGC Pharmaceuticals and have no doubt their respective experience and expertise will be highly valuable. 2020 has been a strategically important year for the Company and strengthening our leadership team with Evan, Sabina and Amir is a testament to how far the Company has come. We are focused on building and strengthening our biopharma specific expertise with high quality people in order to achieve our goals.”

--Ends--

Authorised for release by the Board, for further information please contact:

PR/IR Advisors – Media & Capital Partners

Melissa Hamilton (PR) +61 417 750 274

Rod Hinchcliffe (IR) +61 412 277 377

Melissa.Hamilton@mcpartners.com.au

Rod.Hinchcliffe@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390

info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    